Women with metastatic breast cancer can safely receive bisphosphonates less frequently, without compromising care

Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice change, they may also reduce their risk of serious side effects, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news